doi:10.1038/ijo.2015.59 Jensen SBK, Blond MB, Sandsdal RM, et al
Key Benefits
Li N, Wang JX, Huo TT, Zhao JR, Wang TJ
In terms of appeal, almost half of US GLP-1 users (45%) express some switching preference: for lighter or better-for-you versions of beer and wine, for zero- or low-alcohol versions of their favourites, or for premium quality versions of their favourite drinks now that less is more. Callum Saunders, planning director at brand activation agency Zeal, which works with global brands including Nestl, Carlsberg, and Britvic, is equally upbeat
During the new coronavirus pneumonia epidemic, up to 20% of critically ill patients experienced thromboembolic events during ECMO treatment, which increased the risk for organ failure and death (6668)
Glucagon-like peptide 1 (GLP-1) drugs are revolutionising weight management but with more than half of users discontinuing their treatment within months,1 are current drug delivery solutions failing them